Literature DB >> 24712006

[Surgical treatment of retroperitoneal sarcomas].

Attila Bursics1, István Besznyák1, Tamás Mersich1, Balázs Pörneczi1, Kristóf Dede1, Géza Papp1, Péter Ágoston2, Zsuzsanna Pápai3.   

Abstract

Retroperitoneal sarcomas make up 0.15% of all solid tumors. The mainstay of their treatment is surgical resection, though the removal of the often sizable tumors may pose serious challenge to surgeons. There is no clear-cut recommendation for neoadjuvant, nor for adjuvant treatment so far. We collected the data and recommendations concerning the attributes and the treatment options for retroperitoneal sarcomas. Mainly we focused on the possibilities and the recent change in tactics of surgery. There is no prospective randomized study dealing with surgical treatment of retroperitoneal sarcomas. According to data in the literature the en-block R0 resection along with all the possibly involved neighboring organs offers the best chance for cure. The greatest problem is to define the required resection margin which is needed for R0 resection. Radio- and/or chemotherapy can be used for diminishing the possibility of tumor recurrence. The greatest risk factors for recurrence are incomplete resection, high grade tumor, and non-liposarcoma type histology. Survival depends on local recurrence rather than on distant metastases. Retroperitoneal sarcomas are ideally treated in sarcoma centers, where multidisciplinary consultation is available and complex treatment plans can be set. Complete recovery can be achieved with radical surgical excision. The chance for R0 resection is enhanced by chemo- and radiotherapy.

Entities:  

Mesh:

Year:  2014        PMID: 24712006

Source DB:  PubMed          Journal:  Magy Onkol        ISSN: 0025-0244


  1 in total

1.  A case report of huge perirenal liposarcoma associated with renal cell carcinoma and reviews of three previous cases.

Authors:  Zhe Liu; Yuanhong Xu; Jin Long; Kejian Guo; Ruixia Du
Journal:  Int J Clin Exp Med       Date:  2014-11-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.